Autologous CD7 CAR T-cell / Beijing GoBroad Hospital - LARVOL DELTA

AUTOLOGOUS AND DONOR-DERIVED CD7-KNOCKOUT CD7-TARGETED CAR T THERAPY IN RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1/2 CLINICAL STUDY (EHA 2025) - P1/2 | "For patients without SCT history, if the patient had peripheral tumor burden ≤20% and lymphocytes >0.5×109/L, autologous PBMCs would be preferred; otherwise, PBMCs from a newly HLA-matched donor would be collected.From March 2024 to December 2024, 34 patients were enrolled, including 18 who received autologous CD7 CAR T cells (cohort A), seven who received prior SCT donor-derived CD7 CAR T cells (cohort B), and nine who received newly HLA-matched donor-derived CD7 CAR T cells (cohort C). Patients had comparable response rates to different sources of CD7 CAR T cells. The relatively rapid recovery from severe cytopenias after autologous therapy may underlie a better long-term safety profile. However, the risk of infection after CAR T therapy derived from prior-SCT donor warrants further attention."

Clinical • P1/2 data • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7